Informace o publikaci

Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy

Autoři

RŮŽEK Lukáš KONECNY Tomas SOUČEK Filip KONECNY Dana MACH Lukáš OMMEN Steve R. KOPECKY Stephen L. NISHIMURA Rick A.

Rok publikování 2015
Druh Článek v odborném periodiku
Časopis / Zdroj American Journal of Cardiology
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www http://www.ajconline.org/article/S0002-9149(15)01346-6/abstract
Doi http://dx.doi.org/10.1016/j.amjcard.2015.05.022
Obor Kardiovaskulární nemoci včetně kardiochirurgie
Klíčová slova Hypertrophic cardiomyopathy; male sexual dysfunction; phosphodiesterase type 5; sildenafil
Popis The prevalence of sexual dysfunction (SD) in men with hypertrophic cardiomyopathy (HC) remains unknown, yet its clinical relevance may be high given that its treatment- phosphodiesterase 5 inhibitors (PDE5i)-can increase the left ventricular outflow tract pressure gradient. In this retrospective study, we evaluated the medical records of consecutively seen men with HC for the evidence of SD (defined as SD diagnosis noted in the medical record, the use of medications unique for SD, or SD reported by the patient on a routine clinical questionnaire). Of the 283 consecutively seen men with HC (mean age 52.9 +/- 14.1 years), 63 patients (22%) with SD were identified. Of those with SD, 38% were recorded as regularly using PDE5i. In conclusion, SD and the use of PDE5i present a relatively common occurrence in men with HC, and further studies are needed to develop an evidence-guided algorithm for safe implementation of SD therapies in this most common inherited cardiomyopathy.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info